Prometrium is used to treat secondary amenorrhea, a cessation in menstrual periods for more than six months.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched its generic version of Prometrium capsules for the treatment of secondary amenorrhea, a cessation in menstrual periods for more than six months. The illness is due to a decrease in progesterone. The drug is also given to women together with estrogen-containing medications in postmenopausal women who have not undergone a hysterectomy.
Branded Prometrium, made by Abbott Laboratories Inc. (NYSE: ABT) has $197 million in annual US sales, according to IMS sales data.
Teva's share price fell 2.9% in early trading on the TASE today to NIS 166, after falling 0.1% on Nasdaq on Friday to $45.25, giving a market cap of $40 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on March 4, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012